Tarsus Pharmaceuticals Revenue Climbs 63.9% to $194.5 Million in Q3

GAAP earnings per share was -$14.40. Cash, cash equivalents and marketable securities totaled $309.6 million as of Sept. 30.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.